GlassScriptPhysician profile
Marque Dietzler
NPI 1073968459
$2,367.59
in general payments reported to CMS, 2019-2025
29 companies · $655 in 2025
The $655 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.50 · 2022: $331 · 2023: $386 · 2024: $905 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.89 |
| Education | $259.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396.53 | 2022-2024 | |
| Incyte Corporation | $310.60 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $275.73 | 2023-2025 | Dupixent |
| Genzyme Corporation | $213.63 | 2024-2025 | |
| Amgen INC. | $132.02 | 2023-2025 | Otezla, Otezla, Repatha |
| Janssen Biotech, INC. | $128.91 | 2022-2025 | Tremfya |
| Ucb, INC. | $109.79 | 2024-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $78.77 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $76.48 | 2022-2024 | |
| Novo Nordisk INC | $73.33 | 2021-2025 | Ozempic, Rybelsus |
| Galderma Laboratories, L.P. | $59.94 | 2021-2025 | Nemluvio |
| Lilly USA, LLC | $59.64 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Dermavant Sciences, INC. | $48.79 | 2023-2024 | Vtama |
| Glaxosmithkline, LLC. | $40.76 | 2024 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.70 | 2022-2023 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $33.93 | 2022 | |
| Revance Therapeutics, INC. | $33.93 | 2025 | Daxxify |
| Boston Scientific Corporation | $30.81 | 2023 | Wavewriter Alpha Prime 16 |
| Merz North America, INC. | $27.94 | 2022 | |
| Bioventus LLC | $25.59 | 2022 | |
| Biofrontera INC. | $22.79 | 2022 | |
| Organon LLC | $22.10 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $20.33 | 2025 | Sotyktu |
| Verrica Pharmaceuticals INC. | $19.95 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $19.13 | 2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $19.07 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.39 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $15.94 | 2021 | |
| Astellas Pharma US INC | $15.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marque Dietzler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.